Fitxers
Tipus de document
ArticleVersió
Versió acceptadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/59586
Genomic profile of breast cancer: cost effectiveness analysis from the Spanish National Healthcare System perspective.
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Background: Cost
effectiveness analysis of MammaPrint® (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. Methods: Markov model assuming a cohort of 60-year-old women with breast cancer. Treatment costs and effects were assessed by comparing the 5-year, 10-year and lifetime risk of recurrence using Adjuvant! Online® (online algorithm), 70-gene signature or Oncotype DX® (21-gene assay). Results: 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene assay and online algorithm, with associated quality-adjusted life year gains up to 0.23 and 0.75, respectively, with 70-gene signature. At year 5, the mean cost of 21-gene assay, 70-gene signature and online algorithm was 7100, 6380 and 4580, respectively. 70-gene signature was dominant versus 21-gene assay at any time horizon and would be cost
effective from year 7 versus online algorithm (lifetime: 1457 per quality-adjusted life years gained). Conclusions: 70-gene signature was a dominant strategy over 21-gene assay and was highly cost
effective versus online algorithm.
effectiveness analysis of MammaPrint® (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. Methods: Markov model assuming a cohort of 60-year-old women with breast cancer. Treatment costs and effects were assessed by comparing the 5-year, 10-year and lifetime risk of recurrence using Adjuvant! Online® (online algorithm), 70-gene signature or Oncotype DX® (21-gene assay). Results: 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene assay and online algorithm, with associated quality-adjusted life year gains up to 0.23 and 0.75, respectively, with 70-gene signature. At year 5, the mean cost of 21-gene assay, 70-gene signature and online algorithm was 7100, 6380 and 4580, respectively. 70-gene signature was dominant versus 21-gene assay at any time horizon and would be cost
effective from year 7 versus online algorithm (lifetime: 1457 per quality-adjusted life years gained). Conclusions: 70-gene signature was a dominant strategy over 21-gene assay and was highly cost
effective versus online algorithm.
Matèries (anglès)
Citació
Citació
SEGUÍ, Miquel A., et al. Genomic profile of breast cancer: cost effectiveness analysis from the Spanish National Healthcare System perspective. Expert Review of Pharmacoeconomics & Outcomes Research. 2014. Vol. 14, num. 6, pags. 889-899. ISSN 1473-7167. [consulted: 28 of May of 2026]. Available at: https://hdl.handle.net/2445/59586